489 related articles for article (PubMed ID: 25596769)
61. Recombinant factor VIIa and fibrinogen display additive effect during in vitro haemodilution with crystalloids.
Fenger-Eriksen C; Tønnesen E; Ingerslev J; Sørensen B
Acta Anaesthesiol Scand; 2009 Mar; 53(3):332-8. PubMed ID: 19243319
[TBL] [Abstract][Full Text] [Related]
62. Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study.
Schulman S; Ritchie B; Nahirniak S; Gross PL; Carrier M; Majeed A; Hwang HG; Zondag M;
Thromb Res; 2017 Apr; 152():44-48. PubMed ID: 28222322
[TBL] [Abstract][Full Text] [Related]
63. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model.
Dickneite G; Dörr B; Kaspereit F; Tanaka KA
J Trauma; 2010 May; 68(5):1151-7. PubMed ID: 19996804
[TBL] [Abstract][Full Text] [Related]
64. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
Herrmann R; Thom J; Wood A; Phillips M; Muhammad S; Baker R
Thromb Haemost; 2014 May; 111(5):989-95. PubMed ID: 24352511
[TBL] [Abstract][Full Text] [Related]
65. Treatment of warfarin-related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII.
Pinner NA; Hurdle AC; Oliphant C; Reaves A; Lobo B; Sills A
World Neurosurg; 2010 Dec; 74(6):631-5. PubMed ID: 21492631
[TBL] [Abstract][Full Text] [Related]
66. Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation.
Grottke O; Aisenberg J; Bernstein R; Goldstein P; Huisman MV; Jamieson DG; Levy JH; Pollack CV; Spyropoulos AC; Steiner T; Del Zoppo GJ; Eikelboom J
Crit Care; 2016 Apr; 20(1):115. PubMed ID: 27125504
[TBL] [Abstract][Full Text] [Related]
67. Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit.
Le Saché F; Le Bonniec B; Gaussem P; Dizier B; Tagzirt M; Godier A; Emmerich J; Samama CM
Br J Anaesth; 2012 Apr; 108(4):586-93. PubMed ID: 22258204
[TBL] [Abstract][Full Text] [Related]
68. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood.
Gerotziafas GT; Depasse F; Chakroun T; Samama MM; Elalamy I
Thromb Haemost; 2004 Mar; 91(3):531-7. PubMed ID: 14983229
[TBL] [Abstract][Full Text] [Related]
69. Recombinant factor VIIa does not induce hypercoagulability in vitro.
Gallistl S; Cvirn G; Muntean W
Thromb Haemost; 1999 Feb; 81(2):245-9. PubMed ID: 10064000
[TBL] [Abstract][Full Text] [Related]
70. Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
Jimenez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Martin-Salces M; Hernandez-Navarro F
Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031
[TBL] [Abstract][Full Text] [Related]
71. Hemostatic agents for bleeding: recombinant-activated factor VII and beyond.
Franchini M; Crestani S; Frattini F; Sissa C; Bonfanti C
Semin Thromb Hemost; 2015 Apr; 41(3):342-7. PubMed ID: 24937097
[TBL] [Abstract][Full Text] [Related]
72. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
Szmurło D; Deryło Ł; Ryś P; Władysiuk M
Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998
[TBL] [Abstract][Full Text] [Related]
73. Surgery in patients with haemophilia and high responding inhibitors: Izmir experience.
Balkan C; Karapinar D; Aydogdu S; Ozcan C; Ay Y; Akin M; Kavakli K
Haemophilia; 2010 Nov; 16(6):902-9. PubMed ID: 20518817
[TBL] [Abstract][Full Text] [Related]
74. Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII.
Taketomi T; Szlam F; Levy JH; Tanaka KA
Blood Coagul Fibrinolysis; 2008 Jan; 19(1):106-8. PubMed ID: 18180627
[No Abstract] [Full Text] [Related]
75. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
Zahir H; Brown KS; Vandell AG; Desai M; Maa JF; Dishy V; Lomeli B; Feussner A; Feng W; He L; Grosso MA; Lanz HJ; Antman EM
Circulation; 2015 Jan; 131(1):82-90. PubMed ID: 25403645
[TBL] [Abstract][Full Text] [Related]
76. ROTEM monitoring of activated and non-activated prothrombin complex concentrate correction of dilutional coagulopathy.
Elvstam O; Berntorp E; Schött U
Scand J Clin Lab Invest; 2016; 76(3):202-7. PubMed ID: 26898225
[TBL] [Abstract][Full Text] [Related]
77. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
[TBL] [Abstract][Full Text] [Related]
78. Prothrombin complex concentrates as reversal agents for new oral anticoagulants: lessons from preclinical studies with Beriplex.
Dickneite G
Clin Lab Med; 2014 Sep; 34(3):623-35. PubMed ID: 25168947
[TBL] [Abstract][Full Text] [Related]
79. Dabigatran for the prevention and treatment of thromboembolic disorders.
Enriquez A; Baranchuk A; Redfearn D; Simpson C; Abdollah H; Michael K
Expert Rev Cardiovasc Ther; 2015 May; 13(5):529-40. PubMed ID: 25843430
[TBL] [Abstract][Full Text] [Related]
80. Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect.
Nagakari K; Emmi M; Iba T
Clin Appl Thromb Hemost; 2017 Sep; 23(6):677-684. PubMed ID: 26984934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]